RGS10 (Regulator of G Protein Signaling 10) encodes a member of the RGS family of GTPase-activating proteins that negatively regulate G protein-coupled receptor (GPCR) signaling. Located at chromosome 10q26.11, RGS10 plays critical roles in modulating neuroinflammation, dopaminergic signaling, and microglial activation—processes central to neurodegenerative disease pathogenesis [1][2]. Unlike most RGS proteins, RGS10 is notable for its small molecular weight and distinctive nuclear localization, which confers unique regulatory functions in cellular signaling networks.
RGS10 — Regulator of G Protein Signaling 10
| Symbol | RGS10 |
| Full Name | Regulator of G Protein Signaling 10 |
| Chromosome | 10q26.11 |
| NCBI Gene ID | 6004 |
| OMIM | 602866 |
| Ensembl ID | ENSG00000148991 |
| UniProt ID | Q9NS28 |
| Encoded Protein | RGS10 Protein |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis |
RGS10 is one of the smallest members of the RGS protein family, consisting of approximately 180 amino acids with a conserved RGS domain of about 120 residues [3]. The protein lacks the additional regulatory domains found in larger RGS proteins, such as PDZ or DEP domains, which contributes to its unique subcellular localization and function. The RGS domain adopts a characteristic alpha-helical bundle structure that mediates binding to active Gα subunits and accelerates their GTP hydrolysis activity.
The crystal structure of RGS10 (PDB: 2IHD) reveals a compact, highly stable fold with a unique N-terminal extension that contributes to nuclear localization. Unlike other RGS proteins that primarily localize to the cytoplasm or plasma membrane, RGS10 exhibits prominent nuclear accumulation, suggesting roles in regulating nuclear signaling events and transcriptional responses [4].
RGS10 functions as a GTPase-activating protein (GAP) for heterotrimeric G proteins, specifically targeting Gαi and Gαo subunits. Its catalytic mechanism involves stabilizing the transition state of the GTP hydrolysis reaction, accelerating the rate of GTP hydrolysis by 10-100 fold compared to uncatalyzed rates. This GAP activity terminates GPCR signaling by promoting the inactive Gα-GDP state, which then dissociates from the Gβγ dimer and allows receptor desensitization.
The substrate specificity of RGS10 is determined by the interface between the RGS domain and the Gα subunit, with key contacts occurring at the switch I and switch III regions of Gα. Structural studies have shown that RGS10 recognizes a conserved surface on Gαi/o that is distinct from effector binding sites, enabling selective regulation of GPCR signaling without directly blocking effector interactions [5].
RGS10 exhibits widespread expression throughout the central nervous system, with particularly high levels in regions implicated in neurodegenerative processes [6]:
At the cellular level, RGS10 is expressed in both neuronal and glial populations [7]:
The nuclear localization of RGS10 in neurons is particularly notable, as it suggests functions beyond classical GPCR signal termination. Nuclear RGS10 may regulate gene expression through interactions with transcription factors or chromatin-modifying enzymes.
RGS10 plays a critical role in regulating microglial activation and neuroinflammatory responses [8]. Microglia are the resident immune cells of the central nervous system and serve as the primary defense against pathogens and cellular debris. However, chronic microglial activation contributes to neuroinflammation, a hallmark of virtually all neurodegenerative diseases.
Studies have demonstrated that RGS10 negatively regulates microglial inflammatory responses through multiple mechanisms:
TLR Signaling: RGS10 modulates Toll-like receptor (TLR) signaling, particularly TLR4 activation by lipopolysaccharide (LPS). RGS10 deficiency leads to enhanced pro-inflammatory cytokine production including TNF-α, IL-1β, and IL-6 [9].
GPCR-Mediated Inflammation: RGS10 regulates GPCR signaling that promotes inflammatory responses, including chemokine receptors (CXCR4, CCR5) and nucleotide receptors (P2X7R).
NF-κB Pathway: RGS10 interacts with components of the NF-κB signaling cascade, negatively regulating its activation and downstream inflammatory gene expression.
The anti-inflammatory function of RGS10 has made it an attractive target for neurodegenerative disease therapeutics [10]. Strategies to enhance RGS10 expression or activity could potentially reduce neuroinflammation and slow disease progression. However, the precise molecular mechanisms linking RGS10 to inflammatory signaling remain an active area of investigation.
In Alzheimer's disease (AD), RGS10 expression is altered in brain regions affected by amyloid-beta pathology [11]. Post-mortem studies have demonstrated:
Mechanistically, RGS10 may protect against AD pathogenesis through:
RGS10 is implicated in Parkinson's disease (PD) pathogenesis through its regulation of dopaminergic signaling [12]:
The substantia nigra pars compacta, the primary site of dopaminergic neuron loss in PD, shows altered RGS10 expression that may contribute to increased vulnerability of these neurons to degeneration.
RGS10 expression is also altered in amyotrophic lateral sclerosis (ALS), where neuroinflammation plays a prominent role in disease progression [13]. Microglial activation in ALS is characterized by a complex phenotype that can be both neuroprotective and neurotoxic. RGS10 may help modulate this balance toward a more neuroprotective state.
In multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE), RGS10 plays a dual role [14]:
RGS10 plays a broader role in neuroinflammatory processes beyond microglial activation [15][16]:
Toll-like Receptor Signaling:
Inflammasome Regulation:
Chemokine Signaling:
RGS10 has emerged as a promising therapeutic target for neurodegenerative diseases [17][18][19]:
Anti-inflammatory Strategies:
Disease-Modifying Approaches:
RGS10 is one of the smallest members of the RGS protein family, consisting of approximately 180 amino acids with a conserved RGS domain of about 120 residues [3]. The protein lacks the additional regulatory domains found in larger RGS proteins, such as PDZ or DEP domains, which contributes to its unique subcellular localization and function. The RGS domain adopts a characteristic alpha-helical bundle structure that mediates binding to active Gα subunits and accelerates their GTP hydrolysis activity.
The crystal structure of RGS10 (PDB: 2IHD) reveals a compact, highly stable fold with a unique N-terminal extension that contributes to nuclear localization. Unlike other RGS proteins that primarily localize to the cytoplasm or plasma membrane, RGS10 exhibits prominent nuclear accumulation, suggesting roles in regulating nuclear signaling events and transcriptional responses [4].
RGS10 functions as a GTPase-activating protein (GAP) for heterotrimeric G proteins, specifically targeting Gαi and Gαo subunits. Its catalytic mechanism involves stabilizing the transition state of the GTP hydrolysis reaction, accelerating the rate of GTP hydrolysis by 10-100 fold compared to uncatalyzed rates. This GAP activity terminates GPCR signaling by promoting the inactive Gα-GDP state, which then dissociates from the Gβγ dimer and allows receptor desensitization.
The substrate specificity of RGS10 is determined by the interface between the RGS domain and the Gα subunit, with key contacts occurring at the switch I and switch III regions of Gα. Structural studies have shown that RGS10 recognizes a conserved surface on Gαi/o that is distinct from effector binding sites, enabling selective regulation of GPCR signaling without directly blocking effector interactions [5].
RGS10 regulates multiple GPCR signaling pathways relevant to neurodegeneration:
Emerging evidence suggests RGS10 has functions independent of classical GPCR regulation:
The development of RGS10-targeted therapeutics faces challenges due to the typical protein-protein interaction interface of the RGS domain. However, several strategies are being explored:
RGS10 has potential as a biomarker for neurodegenerative disease diagnosis and progression:
Rgs10-deficient mice have provided important insights into RGS10 function:
Mouse models with altered RGS10 expression:
RGS10 genetic variants have been associated with neurodegenerative diseases: